atrial fibrillation (af) is a commonly encountered arrhythmia in our daily practice. every year a huge bulk of data is published about different management strategies, new antiarrhythmic drugs, anticoagulation protocols and ablation procedures in these patients. in this review article, we discuss different management strategies and new antiarrhythmic drugs as well as those commonly used. we wil...

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

The major limitation to antiarrhythmic drug therapy is the risk of arrhythmia promotion, or 'proarrhythmia.' This complication may be lethal, and greatly restricts the value of antiarrhythmic agents, particularly for arrhythmias without an intrinsic mortality risk, such as atrial fibrillation. In order for improved antiarrhythmic drug therapy to be developed, it is essential to understand the f...

AIMS Catheter ablation of the inferior vena cava-tricuspid annulus isthmus and continuation of antiarrhythmic drug therapy have been shown to be an effective hybrid therapy for atrial flutter which results from antiarrhythmic drug treatment of atrial fibrillation. The aim of this study was to determine the risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy ...

The compound MG-1(R,S), (1-[2-hydroxy-3(4-phenyl-1-piperazinyl)propyl]-pyrrolidin-2-one, and its enantiomers were tested for electrocardiographic, antiarrhythmic and hypotensive activities. The racemic mixture (MG-1(R,S)) and its S-enantiomer significantly decreased systolic and diastolic blood pressure and possessed antiarrhythmic activity. The S-enantiomer displayed the greatest effect. The R...

Most patients with cardiac arrhythmias require treatment with antiarrhythmic drugs, although recent advances in surgical and electrical techniques are promising. The ideal antiarrhythmic compound should have: (1) A wide range of therapeutic activity in both atrial and ventricular arrhythmias. (2) Parenteral and oral formulations to permit simple dosage schedules. (3) Pharmacokinetic properties ...